Free Trial
NASDAQ:BWAY

Brainsway Q2 2025 Earnings Report

Brainsway logo
$12.86 -0.15 (-1.12%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Brainsway EPS Results

Actual EPS
N/A
Consensus EPS
$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Brainsway Revenue Results

Actual Revenue
N/A
Expected Revenue
$12.34 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Brainsway Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Brainsway Earnings Headlines

Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Brainsway Ltd. ADR
See More Brainsway Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Brainsway? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Brainsway and other key companies, straight to your email.

About Brainsway

Brainsway (NASDAQ:BWAY) (NASDAQ: BWAY) is an Israeli medical device company headquartered in Jerusalem that specializes in designing, developing and marketing non-invasive neurostimulation technologies for the treatment of psychiatric and neurological disorders. Founded in 2003, the company’s core mission is to provide safe, drug-free alternatives for patients who have shown inadequate response to conventional therapies.

The company’s flagship offering is the Deep Transcranial Magnetic Stimulation (Deep TMS) system, which utilizes patented H-coil technology to deliver magnetic pulses to specific brain regions. Deep TMS has received U.S. Food and Drug Administration clearances for treatment-resistant depression, obsessive-compulsive disorder and nicotine dependence. Beyond its approved indications, Brainsway is advancing a pipeline of coil configurations and treatment protocols targeting conditions such as anxiety, post-traumatic stress disorder and chronic pain.

Brainsway maintains a global footprint, with direct sales operations and distribution partnerships across North America, Europe, Asia-Pacific and Israel. The company collaborates with leading academic institutions and clinical centers to conduct pivotal trials and expand the scientific evidence supporting its therapies. A dedicated network of clinical trainers and technical service teams ensures healthcare providers receive comprehensive support for implementing and maintaining Deep TMS systems in hospitals, outpatient clinics and specialized treatment centers.

Since its initial public offering on the Nasdaq, Brainsway has steadily grown its installed base of Deep TMS systems while securing broader reimbursement coverage and forging strategic alliances. Under the leadership of Chief Executive Officer Ohad Tal and a management team with deep expertise in medical technology and neuroscience, Brainsway continues to invest in research and development. The company’s ongoing efforts focus on enhancing its existing product portfolio and exploring new applications for non-invasive brain stimulation in mental health and neurological care.

View Brainsway Profile

More Earnings Resources from MarketBeat